Bevacizumab helpful in improving neurocognitive function with aggressive brain cancerBevacizumab (Avastin) based therapy has the potential of making a real difference for patients with glioblastoma.

It was announced by Roche that phase II BRAIN study of bevacizumab alone or in combination with irinotecan chemotherapy for treating relapsed or progressive glioblastoma (GBM) suggested that the drug is effective.

As per William M. Burns, CEO of Roche’s Pharmaceuticals Division, Avastin is able to demonstrate its benefits for proving its worth as an effective treatment option for an increasing variety of cancers.